The high list prices of the injectable medicines Praluent and Repatha — which on average cost more than $14,000 per patient each year in the U.S. — is “uniquely challenging” because they are meant to be lifelong treatments for a growing number of people, according to the study, published Tuesday in the Journal of the American Medical Association. Insurers...